MyeloproliferativeNeoplasmsAn evolving full blood count.

Jennifer Mills

Clinical Scientist: Haematology and Transfusion.

Session Aims



MPN 101

Overview of the disorder and its classifications.



FBC at Presentation

How we diagnose FBC, and how the full blood appears.




FBC and Treatment

Available treatments, and the changes they cause.

FBC and Transformation

How the disorders can transform, and wether that should concern us!!




Haematopoiesis Revision

All blood cells are made in the bone marrow, but only a few enter into peripheral blood (PB).

Megakaryocytes are extremely uncommon in PB.

Red cell precursors are common in anaemia

These cells are normal in peripheral blood.



Blasts are always concerning in peripheral blood!

Myeloid precursors can be present in PB for many reasonsnot all are malignant!

In MPDs, there is an increase in normal, mature cells.

What is an MPD?



What?

- Chronic myeloid disorder.
- Associated with production of normal cells in excess.

Who?

- Can affect any age.
- Many patients can expect to have a normal lifespan



Types

- Polycythaemia Vera
- Essential Thrombocythemia
- Primary Myelofibrosis
- Chronic Myeloid Leukaemia
- Chronic Neutrophilic Leukaemia
- Chronic Eosinophilic Leukaemia

Our focus today is on these 3 disorders.

0

0


	PV/ET/PMF/CML												
~		Feature	S		PV			ET			PMF		
		Associated mutation			JAK2			2/CALR MPL	2/	JAK2,	/CALR/I	MPL	
		Affect on FB	С	↑Hb, ↑ł	Hct, ↑RI	BCC	,	Plts		↓RBCC,	↓WBCC	, ↓Plts	
		Diagnostic Criteria			Hct: >0 ale Hct:		• No	s DOx10 ⁹ / reactiv use		fibros	perythro		
		The Mutation	ns are	not ess		/ou car //ET/PI		gnosed	with tr	iple neç	gative		7

FBC at Presentation


05/11/2020 u/k Blood Request Reason : Hb monito											
_ HB	193 g,			0 to 2		Auth					
WBC		9 * 9/L		0 to 1		Auth					
PLT		9 * 9/L		0 to 4		Auth					
RBC		9 *12/L		0 to 5		Auth					
НСТ	0.578 L,			0 to (Auth					
MCV	93.9 fl			3 to 1	101	Auth					
MCH	31.4 pç	22/12/2022	08:40 B1	ood							
MCHC RDW	16.1	Request Re	eason :		istent	raised	platelets				
MPV	9.4 fl	HR				127	g/L	(120 to 15	50)A	luth
Neutrophils	5.1 10					7.6	10 * 9/L	, (4.0 to 11		luth
Lymphocytes	1.3 10	ОГТ				639	10 × 9/L	(150 to 41		luth
Monocytes	0.6 10	RBC				4.25	10 * 12/L	(3.80 to 4.		luth
		НСТ				0.377	L/L		.360 to 0.		luth
		MCV				88.6	fL	(83 to 10		luth
		MCH				29.9	pg	(27.0 to 32		luth
		MCHC				337	g/L	(315 to 34		luth
		RDW				13.0	5,	(11.6 to 14		luth
		MPV				7.2	fL		7.5 to 11		luth
		Neutrophi	ils			3.2	10 × 9/L	(2.0 to 7.		luth
		Lymphocy				3.6	10 × 9/L		1.0 to 3.		luth
		Monocytes				0.5	10 * 9/L	(0.2 to 1.	.0) A	luth
-											

FBC at Presentation

09/01/2023 08:02 Blood			
Request Reason : MF. HB WBC PLT RBC HCT MCV MCH MCHC RDW MPV Neutrophils Lymphocytes	88 g/L 2.6 10*9/L 14 10*9/L 3.05 10*12/L 0.254 L/L 83.1 fL 28.9 pg 348 10/01/2023 07 Request Reas 0.8 HB 1.3 WBC 0.4 PLT RBC HCT MCV MCH MCH MCH	on: monitoring. 122 g/L 21.0 10 * 1018 10 *	9/L (4.0 to 11.0) Auth 9/L (150 to 410) Auth 12/L (4.50 to 5.50) Auth (0.400 to 0.500) Auth (83 to 101) Auth (27.0 to 32.0) Auth
	RDW MPV Neutrophils Lymphocytes Monocytes	21.6 7.7 fL 20.3 10* 0.2 10* 0.5 10*	



	The	Different	ial Diagn	osis
0		PV	ET	PMF
		Smoking/Hypoxia	Infection	Can appear similar to
	Obesity	Iron Deficiency	patients treated with GCSF, or those with CML.	
Secondary Ca	IUSES	Dehydration	Inflammation	Marrow infiltration by
		Testosterone Abuse	Hyposplenism	metastatic cancer.
		Alcoholism	Bleeding	



Treatment Options

Treatments	Ρ٧	ET	PMF
Aspirin	\checkmark	\checkmark	\checkmark
Hydroxycarbamide	\checkmark	\checkmark	\checkmark
Venesection			
Other available drugs.	Interferon-Alpha Ruxolitinib	Anagrelide Busulfan	Cladribine Interferon-Alpha Thalidomide

Affec	ts of Treatment			
Treatments	Affect			
Aspirin	Reduces thrombotic risk.Dysregulation of platelet function.			
Hydroxycarbamide	 Reduces cell burden. Interferes with the production of DNA. Causes megaloblastic anaemia. Can result in cytopenia's. 			
Venesection	 Reduced red cell burden. Can result in iron restriction (pseudo-iron deficiency) 			


There are several other drugs available, including ruxolitinib, anagrelide, busulfan etc. These drugs can cause cytopenia's, but other side effects tend to be clinical!

FBC and Treatment

Clinical Info:	NHS Number: 450				
ET. Specimen No : HQ847085X	Haematology		ed: 10/01/2023 R > for earlier		
10/01/2023 08:55 Blood Request Reason : ET. HB WBC PLT RBC HCT MCV	137 g/L Rec 6.0 109 408 109 HB 3.65 109 WBC 0.408 L/L PLT	uest Reason :	Lood memory. 143 10.8 630	g/L 10*9/L 10*9/L	(120 to 160) Auth (4.0 to 11.0) Auth (150 to 400) Auth (3.80 to 5.80) Auth
MCHC Request Reason : RDW MPV Neut Lymp Monc HCT MCV	1000 ET on hydroxycar 102 2.0 538 2.48 0.302 122.1	rbamide. g/L 10*9/L 10*9/L 10*12/L L/L fL	(120 to 150 (4.0 to 11.0 (150 to 410 (3.80 to 4.80 (0.360 to 0.460 (83 to 101) Auth	(0.350 to 0.450) Auth (80 to 100) Auth (27.0 to 32.0) Auth (300 to 358) Auth (11.0 to 14.5) Auth (6.5 to 20.0) Auth (2.0 to 7.5) Auth (1.5 to 4.0) Auth (0.2 to 0.8) Auth
MCH MCHC RDW MPV Neutrophils Lymphocytes Monocytes	41.2 337 15.5 8.1 1.1 0.7 0.1	Pg g/L fL 10*9/L 10*9/L 10*9/L	<pre>(27.0 to 32.0</pre>) Auth) Auth) Auth) Auth) Auth) Auth) Auth	

Transformation

Transformation	PV	ET	PMF
Myelofibrosis	\checkmark	\sim	${\overset$
Acute Myeloid Leukaemia	\checkmark	\swarrow	\swarrow



FBC and Transformation

15/03/2022 10:25 Blood Request Reason : Po test.

eason : Polycythaemia, on Ruxolitinib. Pre-Haem clinic blood

HB	111	g/L
WBC	19.7	10 * 9/L
PLT	434	10 * 9/L
RBC	3.35	10 * 12/L
HCT	0.342	L/L
MCV	102.0	fL
MCH	33.1	pg
MCHC	324	g/L
RDW	20.2	
MPV	9.5	fL
Neutrophils	^12.1	10 * 9/L
Neutrophils	11.4	10 * 9/L
Lymphocytes	^3.8	10 * 9/L
Lymphocytes	3.2	10 × 9/L
Monocytes	~2.6	10 × 9/L
Monocytes	2.6	10 * 9/L
Eosinophils	^0.6	10 * 9/L
Eosinophils	0.8	10 * 9/L
BAS	^0.6	10 * 9/L
Basophils	0.4	10 * 9/L
Band Forms	0.4	10 * 9/L
Myelocytes	0.6	10 * 9/L
Blasts		
Automated Nucleated Red Count	^0.3	10 * 9/L
		10.00 (1

	120	to	150		Auth
	4.0	to	11.0		Auth
	150	to	410		Auth
	3.80	to	4.80		Auth
	0.360	to	0.460		Auth
	83	to	101		Auth
	27.0	to	32.0		Auth
(315	to	345)	Auth
((11.6	to	14.0)	Auth
	7.5	to	11.2)	Auth
	2.0	to	7.0		Auth
	2.0	to	7.0		Auth
	1.0	to	3.0		Auth
	1.0	to	3.0		Auth
((0.2	to	1.0)	Auth
	0.2	to	1.0)	Auth
	0.00	to	0.5		Auth
	0.00	to	0.5		Auth
(0.0	to	0.1)	Auth
(0.0	to	0.1)	Auth
					Auth
					Auth
		to			Auth
	0.0	to	0.1		Auth

Polycythaemia Vera transforming to Myelofibrosis.

Counts may not change, or they may develop cytopenia's.

Clinical progression may be more evident, including splenomegaly.

FBC and Transformation

13/10/2022 10:10 Blood		
Request Reason : MF.		
HB WBC PLT RBC HCT MCV MCH MCHC RDW MPV Neutrophils	67 16.6 13 2.35 0.199 85.0 28.7 338 16.8 8.9 ^1.3	fL pg g/L fL 10*9/L
Neutrophils	4.5 ^0.9	10 × 9/L 10 × 9/L
Lymphocytes Lymphocytes Monocytes. Eosinophils Eosinophils BAS Basophils Band Forms Myelocytes Promyelocytes Blasts Atypical Cells Automated Nucleated Red Count	2.2 ^14.4	10*9/L 10*9/L 10*9/L 10*9/L 10*9/L 10*9/L 10*9/L 10*9/L 10*9/L 10*9/L 10*9/L 10*9/L 10*9/L

(130	to	170)	Auth
	4.0	to	11.0		Auth
(150	to	410)	Auth
	4.50	to	5.50		Auth
(0.400	to	0.500		Auth
(83	to	101)	Auth
(27.0	to	32.0)	Auth
(315	to	345		Auth
	11.6	to	14.0		Auth
(7.5	to	11.2)	Auth
((2.0	to	7.0)	Auth
(2.0	to	7.0)	Auth
	1.0	to	3.0		Auth
(1.0	to	3.0))	Auth
(((0.2	to	1.0)	Auth
	0.2	to	1.0		Auth
(0.00	to	0.5))	Auth
	0.00	to	0.5		Auth
(0.0	to	0.1)	Auth
(0.0	to	0.1)	Auth
					Auth
					Auth
					Auth
		to			Auth
					Auth
(0.0	to	0.1)	Auth

Myelofibrosis transforming to Acute Myeloid Leukaemia.

Cytopenia's common as the marrow is busy making blasts.

Unlike MF, blasts will form a significant component of the cells.

When should we act?

First Prese any MPD.

New blast fla leucocytosis known MPD Macrocytosis for patients with known MPD (likely HC treatment), or stable counts, even if the counts are abnormal, can be authorised! penia's on a nown MPD

Significant s in counts own patient e.g. doubling

Thanks!

Do you have any questions?

Jennifer.mills@porthosp.nhs.uk 023 92 28 5774

Please keep this slide for attribution

CREDITS: This presentation template was created by **Slidesgo**, including icons by **Flaticon**, infographics & images by **Freepik**

